Masked Antibodies Show Promise for Intracellular Parkinson's Disease Treatment
Source Summary
Researchers are developing masked antibodies designed to penetrate cell membranes and treat intracellular targets, addressing a major limitation of conventional antibody therapies. Antibody-based treatments have successfully revolutionized medicine for cancer, autoimmune diseases, inflammatory disorders, and infectious diseases, but have been restricted to targeting surface or extracellular molecules. This new approach could expand antibody therapy applications to intracellular Parkinson's disease targets.
Why it matters
Conventional antibodies cannot penetrate cell membranes, limiting their therapeutic use to extracellular targets; masked antibodies could enable treatment of intracellular disease mechanisms previously inaccessible to antibody therapy.
